BMEA Earnings — Biomea Fusion, Inc. Common Stock Post-ER Performance | BigEarnings
BMEA — Biomea Fusion, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.38
Market Cap$99.8M
P/E—
52W Range$0.87 – $3.08
Next Earnings2026-08-04
About Biomea Fusion, Inc. Common Stock
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
